These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 8880970)

  • 21. Clinical diagnosis and staging of prostatic carcinoma.
    Alcini E; D'Addessi A
    Rays; 1993; 18(1):3-13. PubMed ID: 7689236
    [No Abstract]   [Full Text] [Related]  

  • 22. Prognostic significance of obstructive uropathy in advanced prostate cancer.
    Oefelein MG
    Urology; 2004 Jun; 63(6):1117-21. PubMed ID: 15183963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association.
    Cancer Registration Committee of the Japanese Urological Association
    Int J Urol; 2005 Jan; 12(1):46-61. PubMed ID: 15661054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The epidemiology of prostate cancer part I: descriptive epidemiology.
    Brawley OW; Knopf K; Merrill R
    Semin Urol Oncol; 1998 Nov; 16(4):187-92. PubMed ID: 9858324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
    Welch HG; Schwartz LM; Woloshin S
    J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era.
    Descazeaud A; Peyromaure M; Salin A; Amsellem-Ouazana D; Flam T; Viellefond A; Debré B; Zerbib M
    Eur Urol; 2008 Feb; 53(2):355-61. PubMed ID: 17611015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate cancer: a chronic illness.
    Doyle-Lindrud S
    Clin J Oncol Nurs; 2007 Dec; 11(6):857-61. PubMed ID: 18063544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up.
    Vicini FA; Martinez A; Hanks G; Hanlon A; Miles B; Kernan K; Beyers D; Ragde H; Forman J; Fontanesi J; Kestin L; Kovacs G; Denis L; Slawin K; Scardino P
    Cancer; 2002 Nov; 95(10):2126-35. PubMed ID: 12412166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnosis and treatment of prostate cancer.
    Hernandez J; Thompson IM
    Med Clin North Am; 2004 Mar; 88(2):267-79, ix. PubMed ID: 15049578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening for prostate cancer.
    Brawley OW; Ankerst DP; Thompson IM
    CA Cancer J Clin; 2009; 59(4):264-73. PubMed ID: 19564245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate cancer and life insurance.
    Milano AE
    J Insur Med; 2000; 32(2):96-108. PubMed ID: 15912909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Ongoing debates on localized prostate cancer: epidemiology, screening and stratification].
    Audenet F; Rouprêt M
    Prog Urol; 2011 May; 21 Suppl 3():S75-9. PubMed ID: 21616443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic model of event-free survival for patients with androgen-independent prostate carcinoma.
    Shulman MJ; Benaim EA
    Cancer; 2005 Jun; 103(11):2280-6. PubMed ID: 15844202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
    Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P
    Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Explaining the race difference in prostate cancer stage at diagnosis.
    Jones BA; Liu WL; Araujo AB; Kasl SV; Silvera SN; Soler-Vilá H; Curnen MG; Dubrow R
    Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2825-34. PubMed ID: 18829446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for prostate cancer: a urological perspective.
    Fradet Y
    Can J Oncol; 1994 Nov; 4 Suppl 1():8-12. PubMed ID: 8853480
    [No Abstract]   [Full Text] [Related]  

  • 37. Prognostic factors in prostate cancer.
    Stattin P
    Scand J Urol Nephrol Suppl; 1997; 185():1-46. PubMed ID: 9249905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overuse of imaging for staging low risk prostate cancer.
    Choi WW; Williams SB; Gu X; Lipsitz SR; Nguyen PL; Hu JC
    J Urol; 2011 May; 185(5):1645-9. PubMed ID: 21419444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imaging in oncology from the University of Texas M. D. Anderson Cancer Center: diagnosis, staging, and surveillance of prostate cancer.
    Kundra V; Silverman PM; Matin SF; Choi H
    AJR Am J Roentgenol; 2007 Oct; 189(4):830-44. PubMed ID: 17885053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.